ユーロフィン分析科学研究所 List of News Articles

Our company will hold a seminar on E&L testing (extractables and leachables) at INTERPHEX Japan - Pharmaceutical and Cosmetic Manufacturing Expo. We will introduce the fundamental concepts necessary for conducting E&L testing and the optimal design methods that meet regulatory requirements. We invite you to join our seminar at the venue.

Our company will exhibit and hold a seminar at INTERPHEX Japan - Pharmaceutical and Cosmetics Manufacturing Expo - with the following details. <Exhibitor Booth Information> - Date: July 13 (Wednesday) to July 15 (Friday), 2022, 10:00 AM to 6:00 PM (until 5:00 PM on the final day) - Venue: Tokyo Big Sight, West Hall 2 - Booth Number: 19-74 (Contract Manufacturing Zone) - Exhibit Content: Support for formulation development using imaging technology, deformulation technology, E&L testing, elemental impurity testing (ICH-Q3D compliant), foreign matter analysis, nitrosamine measurement, virus vector-related testing, evaluation of biopharmaceuticals and biologically derived pharmaceuticals (mycoplasma detection test, virus clearance test) - Participation Fee: Free <Exhibitor Presentation Information> - Content: Design methods considering the basic concepts and regulatory requirements of E&L testing - Date: July 14 (Thursday), 2022, 12:30 PM to 1:00 PM - Venue: Tokyo Big Sight, West Hall 1, Seminar Room 2 - Participation Fee: Free We invite you to visit our seminar and exhibitor booth. For more details, please refer to "Related Links" and click on "View Company Release Source."

Eurofins Group provides a wide range of analytical and testing services globally across various fields, including food, products, environment, agro, genomics, clinical diagnostics, pharmaceuticals, and materials. In the biopharma services sector, we publish a newsletter three times a year to keep our customers informed with the latest information. The February 2022 issue features the following six technical updates: 1. Eurofins BPT (Toronto, Canada) expands its testing and certification services related to psychedelics to support mental health treatments. 2. Eurofins CDMO assists in solving challenges arising from colon drug delivery in biological products. 3. Organoids: The next step in precision oncology. 4. The future of drug discovery: E3scan and beyond. 5. Eurofins BPT (Italy) expands its testing services for biological products with a fully operational BSL2 facility. 6. Eurofins Central Laboratory addresses challenges in PBMC processing in global clinical trials. Please refer to "Related Links" and view "Company Release Sources" for technical information.

The International Pharmaceutical Development Exhibition 2022 (CPhI/ICSE Japan) was held at Tokyo Big Sight from April 20 to April 22, 2022. Our company participated by exhibiting a booth and conducting a seminar for exhibitors. The booth focused on foreign matter analysis in formulations, elemental impurity testing (ICH-Q3D compliant), formulation development support using surface analysis techniques, E&L (extractables and leachables) testing, mycoplasma testing, virus clearance testing, and virus vector-related testing. In the exhibitor seminar, we presented on the topic "Support for Formulation Development through Foreign Matter Analysis and Imaging Techniques, and Case Studies of Deformulation." In the case of foreign matter analysis, we introduced an analysis of foreign substances contaminating injectable drugs using confocal Raman microscopy. For formulation development support and deformulation case studies, we presented analyses of granules, polymorphism analysis, discoloration tablet analysis, coating particle analysis, and additive grade analysis. For customers who were unable to attend, the exhibitor seminar will be available for video streaming. For more details, please refer to "Related Links" and click on "View Company Release Source."

Our company exhibited at the International Pharmaceutical Development Expo 2022 (April 20-22, 2022). Thank you to everyone who participated. For those who could not attend, we would like to share an overview of our exhibition. At our booth, we discussed foreign matter analysis in formulations, elemental impurity testing (in accordance with ICH-Q3D), formulation development support using surface analysis techniques, E&L (extractables and leachables) testing, mycoplasma testing, virus clearance testing, and virus vector-related testing. In particular, there was significant interest in foreign matter analysis using confocal Raman microscopy. Many customers from manufacturing sites, where foreign matter analysis is crucial, asked whether it was possible to conduct analyses using Raman microscopy, as they could already perform analyses with FT-IR microscopy. During our exhibitor seminar, we presented "Foreign Matter Analysis, Formulation Development Support through Imaging Techniques, and Case Studies of Deformulation." We introduced analyses of foreign matter contaminating injectable products, granule analysis, polymorph analysis, and additive grade analysis using confocal Raman microscopy. For more details, please refer to "Related Links" and view "Company Release Source."

Our company will exhibit and present at the International Pharmaceutical Development Exhibition 2022 (CPhI/ICSE Japan) with the following details. <Exhibitor Booth Information> - Booth Number: 1D-05 - Exhibit Content: Foreign matter analysis in formulations, elemental impurity testing (ICH-Q3D compliant), formulation development support using surface analysis technology, E&L (extractables and leachables) testing, mycoplasma testing, virus clearance testing, virus vector-related testing (New) We will showcase foreign matter analysis in formulations, various formulation development support, elemental impurity testing compliant with ICH-Q3D, and E&L testing, which is part of the ongoing efforts to unify guidelines under ICH-Q3E. Additionally, we will present mycoplasma testing, virus clearance testing, and virus vector-related testing in the biopharmaceutical sector. <Exhibitor Presentation Information> - Content: Introduction of foreign matter analysis, formulation development support using imaging technology, and examples of de-formulation - Date and Time: April 21, 15:30 - 16:00 - Venue: Tokyo Big Sight, East Hall 1, Room 1C We invite you to visit our presentation and exhibitor booth at the venue.

Our company will hold a seminar at the Pharma Lab EXPO Osaka 2022 | Pharmaceutical Research and Development Exhibition. Activities aimed at unifying guidelines for E&L (Extractables and Leachables) testing have begun under ICH-Q3E. Our company is actively transferring innovative analytical technologies from the Eurofins Group in Europe and the United States for E&L testing, accumulating achievements as a leading company in Japan. In this seminar, we will introduce an overview of E&L testing, as well as analytical techniques and measurement examples for micro-contaminants in liquids and contaminants in samples corresponding to BSL-1 (Biosafety Level 1). We invite you to participate in our seminar at the venue.

Our company will exhibit and hold a seminar at the Pharma Lab EXPO Osaka 2022 | Pharmaceutical Research and Development Exhibition with the following details. <Exhibitor Booth Information> - Date: March 9 (Wednesday) - March 11 (Friday), 2022, 10:00 AM - 5:00 PM - Venue: Intex Osaka, Hall 5 - Booth Number: 7-36 (Lab Analysis Zone) - Exhibition Content: Virus vector-related testing, formulation development support using imaging technology, de-formulation technology, E&L (extractables and leachables) testing, elemental impurity testing (ICH-Q3D compliant), foreign matter analysis, nitrosamines measurement, evaluation of biopharmaceuticals and biologically derived pharmaceuticals (mycoplasma detection test, virus clearance test), etc. - Participation Fee: Free *Pre-registration is required <Exhibitor Seminar Information> - Content: Overview of E&L testing and case studies of foreign matter analysis compliant with BSL-1 (Biosafety Level 1) - Date: March 11 (Friday), 2022, 1:20 PM - 1:50 PM - Venue: Intex Osaka *Details of the seminar venue will be provided as soon as they are finalized - Participation Fee: Free For more details, please refer to "Related Links" and click on "View Company Release Source."

We will be exhibiting the following: ● Virus vector-related testing ● Support for formulation development using imaging technology ● Deformulation technology ● E&L (extractables and leachables) testing ● Elemental impurity testing (compliant with ICH-Q3D) ● Foreign substance analysis ● Measurement of nitrosamines ● Evaluation of biopharmaceuticals and biologically derived pharmaceuticals (mycoplasma testing, virus clearance testing) We will showcase our new service "Virus Vector-Related Testing." Eurofins Analytical Science Institute has started accepting quality testing for gene therapy products, including virus vector-related items. We are equipped with a biosafety room compliant with GMP and BSL-2/P2 standards. Additionally, we will present E&L testing, which is part of the ongoing efforts to unify guidelines under ICH-Q3E. E&L testing has been actively transferring innovative analytical technologies from the Eurofins group in Europe and the United States, establishing a track record as a leading company in Japan. Other offerings include elemental impurity testing compliant with ICH-Q3D and measurement of nitrosamines, which have recently been instructed for self-inspection due to contamination risks. Please be sure to visit our exhibition booth.